News: Novartis AG (NOVN.VX)

NOVN.VX on Virt-X Level 1

96.50CHF
3 Jun 2015
Change (% chg)

CHF0.20 (+0.21%)
Prev Close
CHF96.30
Open
CHF96.55
Day's High
CHF96.65
Day's Low
CHF96.20
Volume
122,983
Avg. Vol
4,825,082
52-wk High
CHF102.70
52-wk Low
CHF76.05

Search Stocks
Select another date:

Mon, Jun 1 2015

BRIEF-Novartis says Zykadia data reinforce treatment's efficacy

* Novartis says it is presenting new data from two Phase II studies of Zykadia, as well as one Phase II study of Tafinlar in combination with Mekinist in certain patients with non-small cell lung cancer (NSCLC) to the American Society of Clinical Oncology (ASCO)

Novartis digs into health tech with bet on 'robotic pill'

LONDON - Swiss drugmaker Novartis is raising its bet on smart technology by collaborating with U.S. start-up Rani Therapeutics on a “robotic pill” for complex biotech drugs that would normally have to be given by injection.

Novartis digs into health tech with bet on "robotic pill"

LONDON, May 27 - Swiss drugmaker Novartis is raising its bet on smart technology by collaborating with U.S. start-up Rani Therapeutics on a "robotic pill" for complex biotech drugs that would normally have to be given by injection.

BRIEF-Novartis to present new data at ASCO and EHA

* Says to present new data on 21 medicines and 11 investigational compounds at ASCO and EHA Further company coverage: (Reporting By Zurich Slot)

Par does not infringe Novartis' patents for Alzheimer's patch - Fed. Circ.

- A U.S. appeals court has found that Par Pharmaceutical's copycat version of a patch for Alzheimer's disease-related dementia did not infringe two patents held by the Swiss drugmaker Novartis, helping to clear the way for regulatory approval of the generic drug.

BRIEF-Novartis says lung disease drug studies show positive results

* Novartis says it saw positive results from two Phase III clinical trial programs for QVA149 and NVA237 in patients with moderate-to-severe chronic obstructive pulmonary disease (COPD)

Novartis 'biosimilar' drug blocked by U.S. appeals court

- A U.S. appeals court has blocked the sale of Novartis AG's recently approved "biosimilar" form of Neupogen, the blockbuster Amgen Inc drug used to prevent infections in cancer patients.

Novartis 'biosimilar' drug blocked by U.S. appeals court

- A U.S. appeals court has blocked the sale of Novartis AG's recently approved "biosimilar" form of Neupogen, the blockbuster Amgen Inc drug used to prevent infections in cancer patients.

UPDATE 1-Novartis 'biosimilar' drug blocked by U.S. appeals court

May 7 - A U.S. appeals court has blocked the sale of Novartis AG's recently approved "biosimilar" form of Neupogen, the blockbuster Amgen Inc drug used to prevent infections in cancer patients.

Novartis AG's 'biosimilar' drug sale blocked by U.S. appeals court

May 7 - A U.S. appeals court has blocked the sale of Novartis AG's recently approved "biosimilar" form of Neupogen, Amgen Inc's blockbuster drug used to prevent infections in cancer patients.

Select another date:
Search Stocks